3D Systems (DDD) Q1 2026 earnings review
Core Growth Returns, but Profitability Remains Fragile
3D Systems finally demonstrated that its aggressive cost-cutting and portfolio rationalization are paying off. Adjusted EBITDA flipped to a positive $2.1 million—a massive $26 million swing from a year ago. Adjusting for 2025 software divestitures (Geomagic, 3DXpert, Oqton), core revenue grew 11% YoY, propelled by a 21% surge in the Healthcare segment. However, Q2 guidance pours cold water on the immediate celebration, projecting a return to negative EBITDA. The path to consistent profitability remains bumpy, heavily reliant on sustained brutal cost containment rather than explosive top-line scale.
🐂 Bull Case
The company successfully removed massive costs from its structure. Non-GAAP operating expenses plummeted from $61.6M in 25Q1 to $36.6M in 26Q1, allowing the company to generate positive EBITDA on a flat reported revenue base.
Healthcare solutions surged 21% YoY to $50.1M, officially overtaking Industrial ($45.4M) as the primary revenue driver, led by >20% growth in Med Tech and Dental (excluding aligners).
🐻 Bear Case
Despite celebrating a positive Adjusted EBITDA in Q1, management guided 26Q2 Adjusted EBITDA to a range of $(4)M to $(2)M. The operational leverage is not yet strong enough to sustain consistent profitability without perfect execution.
Reported Industrial revenue fell 15% YoY. Even adjusting for divestitures, the segment only grew 2%—a lackluster performance that highlights ongoing macro hesitation in broad capital equipment purchasing.
⚖️ Verdict: ⚪
Neutral. The transition from massive cash burn to positive EBITDA is commendable and proves management is executing on its structural promises. However, the Reversing trend indicated by negative Q2 guidance shows the company hasn't fully escaped the multi-year macro downturn.
Key Themes
Aggressive OpEx Slashes Drive the Bottom Line
The return to positive Adjusted EBITDA was not driven by scale, but by the knife. Non-GAAP operating expenses have been Decelerating rapidly over the last four quarters, falling to $36.6M in 26Q1 from $61.6M a year ago. R&D was cut by more than half (down to $9.6M from $19.7M GAAP) and SG&A dropped sharply. Management is successfully extracting the promised $70M+ in annualized savings.
Healthcare Becomes the Crown Jewel
Healthcare is Accelerating, growing ~21% YoY to $50.1M. This segment has now structurally surpassed Industrial ($45.4M) in size. The growth is high-quality, driven by >20% spikes in Med Tech (fueled by PEEK material trauma applications) and Dental, excluding the volatile aligner business. The rollout of advanced printing systems for monolithic dentures is gaining real traction.
Aerospace & Defense Ignites Industrial Growth
While broad Industrial reported a 15% drop (due to software divestitures), the underlying core grew 2%. The standout was Aerospace & Defense, which grew over 20%. Key catalysts include a new American Formula 1 team deploying 3D Systems' SLA technology and early success with high-performance metal components, validating the DMP hardware platform.
Q2 Guidance Contradicts the Turnaround Narrative
Management touted their return to a positive $2.1M Adjusted EBITDA, but 26Q2 guidance explicitly forecasts a Reversing trend to $(4)M to $(2)M. If OpEx is permanently lowered, this suggests an expected sequential deterioration in gross margins or unfavorable product mix (likely lower-margin printers vs higher-margin materials). Achieving the 'full-year break-even' target now requires a flawless second half.
R&D Cuts: Mortgaging the Future?
GAAP R&D spending plummeted by 51% YoY ($19.7M down to $9.6M). While management previously stated their '3-year product refresh' was complete, maintaining such a dramatically lower investment rate in the hyper-competitive additive manufacturing space risks ceding technology leadership to better-funded rivals over the medium term.
Macro Destocking and CapEx Hesitation Lingers
The company notes the industry is 'beginning to emerge from a multi-year downturn.' However, global economic uncertainty and tariff-related risks continue to pressure broad capital investments. Management's conservative Q2 revenue guidance indicates they are still battling cautious purchasing behavior from global manufacturers.
Other KPIs
Stable. Up from 35.0% in 25Q1. Software divestitures typically drag margins down (since software carries near-100% margins), but adjusting for the loss of Geomagic and Oqton, core hardware/materials Non-GAAP gross margin actually expanded by a massive 600 basis points. This reflects excellent manufacturing execution and favorable shift toward high-margin medical materials.
Total cash ended Q1 at $86.5M. The company has essentially cleared its near-term maturity runway, with only $3.9M due in late 2026, and the remaining $92.0M pushed to 2030. The cash buffer is sufficient provided they execute their break-even target.
Guidance
Decelerating sequentially. The midpoint of $94.0M represents a step down from 26Q1's $95.5M. This signals that despite strong Healthcare performance, broad industrial purchasing remains lumpy and macro hesitation persists.
Reversing. After achieving positive $2.1M in Q1, the company expects to slide back into the red. Management maintained a 'full-year break-even' target, which mathematically implies the second half of 2026 must generate positive EBITDA to offset the guided Q2 loss.
Key Questions
Margin vs. Mix Dynamics
With 26Q2 revenue guided relatively flat sequentially ($94M midpoint vs $95.5M actual), what is driving the projected sequential drop in Adjusted EBITDA back into negative territory? Is this driven by a shift in sales mix from materials toward lower-margin hardware?
R&D Sustainability
R&D expenses have been cut by over 50% year-over-year. While the recent portfolio refresh is complete, how do you ensure the pipeline remains competitive in rapidly evolving areas like monolithic dentures and AI thermal management?
Aligner Market Stabilization
In 2025, the dental aligner business faced severe volatility due to a major customer's transition to just-in-time inventory. Has this inventory destocking fully normalized, and is the aligner segment now a stable baseline for 2026?